Cargando…

Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma

BACKGROUND & AIMS: Immune checkpoint inhibitors (ICIs) alone or in combination with other ICIs or vascular endothelial growth factor pathway inhibitors are therapeutic options in unresectable/metastatic hepatocellular carcinoma (HCC). Whether antibiotic (ATB) exposure affects outcome remains unc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pinato, David J., Li, Xiaoxue, Mishra-Kalyani, Pallavi, D’Alessio, Antonio, Fulgenzi, Claudia A.M., Scheiner, Bernhard, Pinter, Matthias, Wei, Guo, Schneider, Julie, Rivera, Donna R., Pazdur, Richard, Theoret, Marc R., Casak, Sandra, Lemery, Steven, Fashoyin-Aje, Lola, Cortellini, Alessio, Pelosof, Lorraine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183666/ https://www.ncbi.nlm.nih.gov/pubmed/37197442 http://dx.doi.org/10.1016/j.jhepr.2023.100747

Ejemplares similares

Systematic Review of PD‐1/PD‐L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
por: Chang, Elaine, et al.
Publicado: (2021)

Benefit‐Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib
por: Pelosof, Lorraine, et al.
Publicado: (2018)

PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects
por: D’Alessio, Antonio, et al.
Publicado: (2021)

FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1
por: Fashoyin‐Aje, Lola, et al.
Publicado: (2018)

To Adjudicate or Not Adjudicate: That Is the Question
por: Hicks, Karen A., et al.
Publicado: (2022)

Immunotherapy in Hepatocellular Carcinoma
por: Fulgenzi, Claudia A. M., et al.
Publicado: (2021)

Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials
por: Kanapuru, Bindu, et al.
Publicado: (2022)

Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond
por: Lemery, Steven, et al.
Publicado: (2022)

Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer
por: Kazandjian, Dickran, et al.
Publicado: (2016)

Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma
por: Manfredi, Giulia Francesca, et al.
Publicado: (2023)

Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data
por: Maignan, Kathleen, et al.
Publicado: (2022)

Assessing the Needs of Those Who Serve the Underserved: A Qualitative Study among US Oncology Clinicians
por: Patel, Manali I., et al.
Publicado: (2023)

Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
por: Mulkey, Flora, et al.
Publicado: (2020)

ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma
por: Demirtas, Coskun O., et al.
Publicado: (2021)

Action for Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials—Is Africa the Answer? Report From a Satellite Session of the Accelerating Anti-Cancer Agent Development and Validation Workshop
por: Kizub, Darya, et al.
Publicado: (2022)

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study
por: D’Alessio, Antonio, et al.
Publicado: (2022)

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2022)

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
por: Wu, Yue Linda, et al.
Publicado: (2022)

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
por: Vithayathil, Mathew, et al.
Publicado: (2023)

US Food and Drug Administration regulatory updates in neuro-oncology
por: Mehta, Gautam U., et al.
Publicado: (2021)

The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC
por: Cortellini, Alessio
Publicado: (2020)

Oncology approvals in 2020: a year of firsts in the midst of a pandemic
por: Amiri-Kordestani, Laleh, et al.
Publicado: (2021)

Role of Endothelial Cell Metabolism in Normal and Tumor Vasculature
por: D’Alessio, Alessio
Publicado: (2023)

The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma
por: Muhammed, Ambreen, et al.
Publicado: (2021)

Caveolae and Lipid Rafts in Endothelium: Valuable Organelles for Multiple Functions
por: Filippini, Antonio, et al.
Publicado: (2020)

Cell Death
por: Giampietri, Claudia, et al.
Publicado: (2014)

Transcriptomic analysis of pancreatic adenocarcinoma specimens obtained from Black and White patients
por: Biel, Thomas G., et al.
Publicado: (2023)

Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
por: Xie, Enrui, et al.
Publicado: (2023)

AP® statistics crash course, for the 2020 exam, book + online
por: D'Alessio, Michael
Publicado: (2020)

Is GLP‐1 a hormone: Whether and When?
por: D'Alessio, David
Publicado: (2016)

The Transcriptional Signature in Alveolar Macrophages Dictates Acute Respiratory Distress Outcomes
por: Tejwani, Vickram, et al.
Publicado: (2019)

Endothelial Cell Metabolism in Vascular Functions
por: Filippini, Antonio, et al.
Publicado: (2022)

Message in a Bottle: Endothelial Cell Regulation by Extracellular Vesicles
por: Palazzo, Claudia, et al.
Publicado: (2022)

Taking Aim at Islet Hormones With GLP-1: Is Insulin or Glucagon the Better Target?
por: D'Alessio, David A.
Publicado: (2010)

Learning lessons from the COVID-19 pandemic for real-world evidence research in oncology—shared perspectives from international consortia
por: Castelo-Branco, L., et al.
Publicado: (2023)

Calcium Mobilization in Endothelial Cell Functions
por: Filippini, Antonio, et al.
Publicado: (2019)

Taxonomic reclassification of Kaposi Sarcoma identifies disease entities with distinct immunopathogenesis
por: Openshaw, M. R., et al.
Publicado: (2023)

One more piece to SOLIDify our knowledge on the impact of SARS-CoV-2 in patients with cancer
por: Addeo, Alfredo, et al.
Publicado: (2022)

An Innate Disposition for a Healthier Gut: GLP-1R Signaling in Intestinal Epithelial Lymphocytes
por: Rosario, Wilfredo, et al.
Publicado: (2015)

Evidence of Reelin Signaling in GBM and Its Derived Cancer Stem Cells
por: Biamonte, Filippo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9ttdsdvgtrpior812n9l02p477